Search

Lazertinib

[A264289] It was approved by the FDA on August 19, 2024.[L51189] Lazertinib is used alone or in combination with other chemotherapeutic agents.[L51184] … [A264299, A264304] Lazertinib was first approved in South Korea on January 18, 2021, for the treatment of _EGFR_ T790M mutation-positive non-small cell lung cancer (NSCLC) with EGFR mutations.

Sodium molybdate

Linaclotide

Linaclotide is a synthetic 14-amino acid cyclic peptide [A260271] and first-in-class guanylate cyclase-C (G-CC) agonist. … [A260276] It is also a homolog of a heat-stable enterotoxin derived from _Escherichia coli_, the first natural ligand that activates GC-C.

Reslizumab

It is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines. Reslizumab is marketed as Cinqaero in Europe. … Patients often experience persistent or exacerbating symptoms overtime despite conventional first-line therapies available.

Crizotinib

[L42460] By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement … [A250785] Crizotinib was the first-in-class drug used to treat ALK-positive tumors.

Rotigotine

Rotigotine (Neupro) is a non-ergoline dopamine agonist indicated for the treatment of Parkinson's disease (PD) and restless legs syndrome (RLS) in Europe and the United States. … However, all Neupro patches in the United States and some of Europe were recalled in 2008 due to delivery mechanism issues. Rotigotine has been authorized as a treatment for RLS since August 2008.

Cetalkonium

[L2137] Cetalkonium is approved by the FDA for its use in over-the-counter products as a skin protectant.[L2737] By Health Canada, it is also approved for its use in over-the-counter products.[L1113] … Cetalkonium is a C16 alkyl benzalkonium chloride derivative with an amphipathic property which allows it to be used in different types of formulations.

Finasteride

[L6244,L10565] In 1998, it was approved by the FDA to treat male pattern hair loss. … It works in a similar fashion as [dutasteride], which is another 5-alpha-reductase inhibitor, by exerting antiandrogenic effects.

Baloxavir marboxil

[A251760] Baloxavir marboxil was first globally approved in Japan in February 2018,[A39895] followed by the US approval in October, 2018. … [L4779] It was also approved by the European Commission on January 7, 2021.[L45241]

Tauroursodeoxycholic acid

[A249080] Tauroursodeoxycholic acid is currently used in Europe to treat and prevent gallstones as a bile acid derivative. … Tauroursodeoxycholic acid, also known as ursodoxicoltaurine, is a highly hydrophilic tertiary bile acid [A249070] that is produced in humans at a low concentration.